Paradigm Health has raised $78 million as it works to revamp the clinical research ecosystem, while also announcing a deal to ...

Lagging behind the PD-1xVEGF leaders, Crescent has strengthened its hand by licensing Kelun’s integrin beta-6 ...

Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to ...

The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...

The FDA has named Tracy Beth Høeg, M.D., Ph.D., as acting director of its Center for Drug Evaluation and Research, continuing ...

In 2003, Medtronic first received a humanitarian green light from the FDA to offer its deep brain stimulation implants to ...

GE HealthCare and the Mayo Clinic are expanding their long-running collaborative work to now include the development of new personalized radiation therapy approaches for cancer, with a pl | The ...

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...

The FDA has proposed cutting fees for early-stage companies conducting clinical development in the U.S. instead of abroad. | ...

Investigators randomized 134 people with hereditary angioedema (HAE) to receive deucrictibant or placebo. Participants took ...

Triana Biomedicines has tapped Pfizer Ventures and a number of other existing and new investors to secure a $120 million ...

In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...